Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation.

By Roger P Leng, Yunping Lin, Weili Ma, Hong Wu, B. Lemmers, S. Chung, J. Parant, G. Lozano, R. Hakem, S. Benchimol. Cell, 2003

791 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/b748048b10fbeb531875dcca9b0f892270b1fb4d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Jian Lei
2. Arnold J. Levine
3. Karen H. Vousden
4. Rolf Hilgenfeld
5. Bin Liu
6. Y. Kusov

In Molecular Biology

1. W. Gu
2. Karen H. Vousden
3. C. Brooks
4. Yingming Zhao
5. Yi Tang
6. S. Harris
7. Yue Chen
8. Arnold J. Levine

In Oncology

1. W. Gu
2. Karen H. Vousden
3. Yingming Zhao
4. C. Brooks
5. Arnold J. Levine
6. Yi Tang
7. S. Harris
8. Yue Chen

Citations in the corpus

• Regulating the p53 pathway: in vitro hypotheses, in vivo veritas (2006, background): “Future in vivo analyses will be crucial to evaluate the importance of other proposed p53 regulators, such as PIRH2, COP1 and ARF–BP1 (Ref”
• The p53 pathway: positive and negative feedback loops (2005, background): “Surprisingly, there appears to be three different p53-ubiqutin ligase activities (MDM-2, Cop-1 and Pirh-1), each of which forms an autoregulatory loop resulting in lower p53 activity (Leng et al., 2003; Dornan et al., 2004) (Figure 10).”
• Acetylation is indispensable for p53 activation. (2008, background): “To extend these findings, we identified Pirh2 as another p53 target (Leng et al., 2003), whose induction by p53 is independent of the acetylation status (Figure S10).”
• Regulation of HDM2 activity by the ribosomal protein L11. (2003, background): “Pirh2, a p53-inducible K.H. (1996).”
• Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein (2017, background): “Like MDM2, RCHY1 can induce p53 degradation as well (Leng et al., 2003).”
• The complexity of p53 stabilization and activation (2006, background): “While controversy surrounds the importance of p53 ser20 phos- phorylation in its stabilization, there is at least some evidence that this modification reduces interaction with MDM2.”
• Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary (2010, background): “Of the remaining mutation-negative cases, three may have had inactivation of the p53 pathway through chromosomal gain at the MDM2 or MDM4 loci or potentially other genes that alter p53 function in trans such as RFWD2 and RCHY1 [25,26].”